Literature DB >> 9145888

In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

O Uzun1, S Kocagöz, Y Cetinkaya, S Arikan, S Unal.   

Abstract

The in vitro activity of LY303366, a new echinocandin derivative, was evaluated with 191 yeast isolates by a broth microdilution method. The MICs at which 50% of the isolates were inhibited were 0.125 microg/ml for Candida albicans and C. tropicalis, 0.25 microg/ml for C. krusei, C. kefyr, and C. glabrata, and 2.0 microg/ml for C. parapsilosis.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9145888      PMCID： PMC163869     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.

Authors:  M Akova; H E Akalin; O Uzun; D Gür
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

Review 3.  Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review.

Authors:  E Anaissie
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

4.  Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.

Authors:  E J Anaissie; S E Vartivarian; D Abi-Said; O Uzun; H Pinczowski; D P Kontoyiannis; P Khoury; K Papadakis; A Gardner; I I Raad; J Gilbreath; G P Bodey
Journal:  Am J Med       Date:  1996-08       Impact factor: 4.965

5.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

6.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

7.  Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

Authors:  M L Cameron; W A Schell; S Bruch; J A Bartlett; H A Waskin; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading.

Authors:  E Anaissie; V Paetznick; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191
  8 in total
  22 in total

1.  Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids.

Authors:  K V Clemons; R A Sobel; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.

Authors:  Gloria N Mattiuzzi; Gladys Alvarado; Francis J Giles; Luis Ostrosky-Zeichner; Jorge Cortes; Susan O'brien; Srdan Verstovsek; Stefan Faderl; Xian Zhou; Issam I Raad; B Nebiyou Bekele; G J Leitz; Ivonne Lopez-Roman; Elihu H Estey
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature.

Authors:  Corrado Girmenia; Livio Pagano; Bruno Martino; Domenico D'Antonio; Rosa Fanci; Giorgina Specchia; Lorella Melillo; Massimo Buelli; Giampaolo Pizzarelli; Mario Venditti; Pietro Martino
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 4.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

5.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains.

Authors:  Lei Shao; Jian Li; Aijuan Liu; Qing Chang; Huimin Lin; Daijie Chen
Journal:  Appl Environ Microbiol       Date:  2012-12-07       Impact factor: 4.792

7.  Evaluation of endpoints for antifungal susceptibility determinations with LY303366.

Authors:  M E Klepser; E J Ernst; M E Ernst; S A Messer; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Trichosporon inkin peritonitis treated with caspofungin.

Authors:  Miguel G Madariaga; Allan Tenorio; Laurie Proia
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

10.  In vitro activity of anidulafungin against selected clinically important mold isolates.

Authors:  Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.